Literature DB >> 29545434

Management of tumour lysis syndrome during first-line palliative chemotherapy for high-volume colorectal cancer.

Helena S Gouveia1, Sílvia O Lopes2, Ana Luísa Faria1.   

Abstract

Tumour lysis syndrome (TLS) is a rare oncological emergency in solid tumours. Because it is associated with bad short-term prognosis, early recognition and treatment are mandatory. This case refers to a middle-aged woman who presented with stage IV colon cancer, with massive hepatic involvement. After three cycles of first-line FOLFOX (folinic acid, 5-fluorouracil and oxaliplatin), she developed acute kidney injury and hyperkalaemia that did not respond to standard measures. High suspicion of TLS prompted further corroborating investigations and early intensive care unit admission. With vigorous hydration and allopurinol, TLS completely resolved and the patient was discharged. Prophylaxis of subsequent TLS recurrence was complicated by biopsy-proven neutrophilic vasculitis secondary to allopurinol. Prevention of TLS with hydration and rasburicase was performed prior to each subsequent cycle of chemotherapy. This case report is intended to highlight risk factors for TLS in solid tumours and focus on treatment and secondary prophylaxis of TLS. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  acute renal failure; chemotherapy; colon cancer; fluid electrolyte and acid-base disturbances

Mesh:

Substances:

Year:  2018        PMID: 29545434      PMCID: PMC5878355          DOI: 10.1136/bcr-2017-223474

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  26 in total

1.  [Tumor lysis syndrome after chemotherapy for colon small cell carcinoma].

Authors:  O El Mesbahi; A Beaudoin; C Louvet; A De Gramont
Journal:  Rev Med Interne       Date:  2004-10       Impact factor: 0.728

Review 2.  Tumor Lysis Syndrome in Metastatic Colon Cancer Following Treatment with Regorafenib.

Authors:  Bilal Farooqi; Josh Simmons; Zhonglin Hao
Journal:  J Gastrointest Cancer       Date:  2015-09

Review 3.  Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus.

Authors:  Mitchell S Cairo; Bertrand Coiffier; Alfred Reiter; Anas Younes
Journal:  Br J Haematol       Date:  2010-03-16       Impact factor: 6.998

Review 4.  Management of tumor lysis syndrome in adults.

Authors:  Bertrand Coiffier; Catherine Riouffol
Journal:  Expert Rev Anticancer Ther       Date:  2007-02       Impact factor: 4.512

5.  Rapid tumour lysis syndrome in a metastatic colorectal cancer increased by treatment (CPT-11)

Authors:  M Boisseau; R Bugat; M Mahjoubi
Journal:  Eur J Cancer       Date:  1996-04       Impact factor: 9.162

6.  Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology.

Authors:  Gail L Jones; Andrew Will; Graham H Jackson; Nicholas J A Webb; Simon Rule
Journal:  Br J Haematol       Date:  2015-04-15       Impact factor: 6.998

Review 7.  The tumor lysis syndrome.

Authors:  Scott C Howard; Deborah P Jones; Ching-Hon Pui
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

8.  Colorectal cancer: dilemmas regarding patient selection and toxicity prediction.

Authors:  Z Nikolic-Tomasevic; S Jelic; I Popov; D Radosavljevic
Journal:  J Chemother       Date:  2000-06       Impact factor: 1.714

Review 9.  Tumor lysis syndrome in small cell carcinoma and other solid tumors.

Authors:  G P Kalemkerian; B Darwish; M L Varterasian
Journal:  Am J Med       Date:  1997-11       Impact factor: 4.965

10.  Spontaneous tumor lysis syndrome in colon cancer: a case report and literature review.

Authors:  David Sommerhalder; Amol M Takalkar; Rodney Shackelford; Prakash Peddi
Journal:  Clin Case Rep       Date:  2017-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.